专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

81. 发明授权

US08431553B2 Combination of methylxanthine compounds and steroids to treat chronic respiratory diseases 有权
标题翻译：甲基黄嘌呤化合物和类固醇联合治疗慢性呼吸道疾病
公开(公告)号：US08431553B2
公开(公告)日：2013-04-30
申请号：US11883635
申请日：2006-02-13
申请人： Justian Craig Fox , Mary Frances Fitzgerald , Harry Finch
发明人： Justian Craig Fox , Mary Frances Fitzgerald , Harry Finch
IPC分类号： A01N45/00 , A61K31/56
CPC分类号： A61K31/58 , A61K31/52 , A61K2300/00
摘要： There is provided the use of a methylxanthine derivative such as theophylline and a steroid in a synergistic combination for the treatment of chronic obstructive pulmonary disease, wherein the combination is administered by the inhaled route for pulmonary delivery.
摘要翻译：提供甲基黄嘌呤衍生物如茶碱和类固醇在协同组合中用于治疗慢性阻塞性肺疾病的用途，其中所述组合通过用于肺部递送的吸入途径施用。

82. 发明授权

US08394836B2 Indoles and their therapeutic use 有权
标题翻译：吲哚及其治疗用途
公开(公告)号：US08394836B2
公开(公告)日：2013-03-12
申请号：US12746104
申请日：2008-12-12
申请人： George Hynd , John Gary Montana , Harry Finch , Rosa Arienzo , Barbara Avitabile-Woo , Mathias Domostoj
发明人： George Hynd , John Gary Montana , Harry Finch , Rosa Arienzo , Barbara Avitabile-Woo , Mathias Domostoj
IPC分类号： A61K31/4439 , C07D409/12 , C07D401/12
CPC分类号： C07D209/12 , C07D209/04 , C07D401/06 , C07D403/06 , C07D403/12 , C07D409/06 , C07D409/14 , C07D417/06 , C07D417/14
摘要： Compound of formula (I) are ligands of the CRTH2 receptor, useful inter alia for treatment of inflammatory conditions. Wherein X is —SO2— or *—SO2NR3— wherein the bond marked with an asterisk is attached to Ar1; R1 is hydrogen, fluoro, chloro, CN or CF3; R2 is hydrogen, fluoro or chloro; R3 is hydrogen, C1C8alkyl or C3-C7cycloalkyl; Ar1 is phenyl or a 5- or 6-membered heteroaryl group selected from furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C3-C7cycloalkyl, —O(C1-C4alkyl) or C1C6alkyl, the latter two groups being optionally substituted by one or more fluoro atoms; and Ar2 is phenyl or 5- or 6-membered heteroaryl group selected from pyrrolyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C3-C3-C7cycloalkyl, —O(C1-C4alkyl) or C1C6alkyl, the latter two groups being optionally substituted by one or more fluoro atoms.
摘要翻译：式（I）的化合物是CRTH2受体的配体，特别用于治疗炎性病症。其中X是-SO 2 - 或* -SO 2 NR 3 - ，其中用星号附着的键连接到Ar1上; R1是氢，氟，氯，CN或CF3; R2是氢，氟或氯; R3是氢，C1C8烷基或C3-C7环烷基; Ar 1是苯基或选自呋喃基，噻吩基，恶唑基，噻唑基，咪唑基，吡唑基，异恶唑基，异噻唑基，吡啶基，哒嗪基，嘧啶基和吡嗪基的5-或6-元杂芳基，其中苯基或杂芳基任选被一个或更多个独立地选自氟，氯，CN，C 3 -C 7环烷基，-O（C 1 -C 4烷基）或C 1 -C 6烷基的取代基，后两个基团任选被一个或多个氟原子取代; 并且Ar 2是苯基或选自吡咯基，呋喃基，噻吩基，恶唑基，噻唑基，咪唑基，吡唑基，异恶唑基，异噻唑基，吡啶基，哒嗪基，嘧啶基和吡嗪基中的5-或6-元杂芳基，其中苯基或杂芳基任选被取代通过一个或多个独立地选自氟，氯，CN，C 3 -C 3 -C 7环烷基，-O（C 1 -C 4烷基）或C 1 -C 6烷基的取代基，后两个基团任选被一个或多个氟原子取代。

83. 发明授权

US08394830B2 Quinolines and their therapeutic use 有权
标题翻译：喹啉及其治疗用途
公开(公告)号：US08394830B2
公开(公告)日：2013-03-12
申请号：US13435242
申请日：2012-03-30
申请人： John Gary Montana , Harry Finch , George Hynd , Michael Colin Cramp , Rosa Arienzo , Neville McLean
发明人： John Gary Montana , Harry Finch , George Hynd , Michael Colin Cramp , Rosa Arienzo , Neville McLean
IPC分类号： A61K31/04
CPC分类号： C07D401/10 , C07D215/227 , C07D215/233 , C07D413/10 , C07D417/10
摘要： Compounds of formula (I) are CRTH2 ligands, useful in the treatment of, for example, asthma and COPD wherein: R1 is halogen or cyano; R2 is hydrogen or methyl; R3 and R4 are independently —OR6, C1-C6alkyl or C3-C6cycloalkyl, the latter two groups being optionally substituted by one or more halogen atoms; R5 is hydrogen or halogen; R6 is C1C6alkyl or C3-C6cycloalkyl, either of which being optionally substituted by one or more halogen atoms; X is —CH2—, —S—, or —O—; one of Y and Y1 is hydrogen and the other is OR6, —C(═O)R7, NR8SO2R6 or a heterocyclic group selected from those referred to in the specification; and R6, R7 and R8 are as defined in the specification.
摘要翻译：式（I）化合物是可用于治疗例如哮喘和COPD的CRTH2配体，其中：R1是卤素或氰基; R2是氢或甲基; R 3和R 4独立地为-OR 6，C 1 -C 6烷基或C 3 -C 6环烷基，后两个基团任选被一个或多个卤素原子取代; R5是氢或卤素; R6是C1C6烷基或C3-C6环烷基，其中任一个任选被一个或多个卤素原子取代; X是-CH 2 - ， - S-或-O-; Y和Y1中的一个是氢，另一个是选自本说明书中提到的那些的OR 6，-C（= O）R 7，NR 8 SO 2 R 6或杂环基; R6，R7和R8如说明书中所定义。

84. 发明申请

US20120252797A1 Isoxazole Compounds As Inhibitors Of Heat Shock Proteins 有权
标题翻译：异恶唑化合物作为热休克蛋白的抑制剂
公开(公告)号：US20120252797A1
公开(公告)日：2012-10-04
申请号：US13525409
申请日：2012-06-18
申请人： Martin James Drysdale , Brian William Dymock , Harry Finch , Paul Webb , Edward McDonald , Karen Elizabeth James , Kwai Ming Cheung , Thomas Peter Matthews
发明人： Martin James Drysdale , Brian William Dymock , Harry Finch , Paul Webb , Edward McDonald , Karen Elizabeth James , Kwai Ming Cheung , Thomas Peter Matthews
IPC分类号： A61K31/42 , C07D413/10 , A61K31/5377 , A61K31/422 , A61K31/4439 , A61P35/00 , A61K31/427 , C07D413/14 , A61K31/496 , A61K31/454 , A61K31/541 , C07D261/08 , C07D417/04
CPC分类号： A61K31/541 , A61K31/42 , A61K31/422 , A61K31/427 , A61K31/4439 , A61K31/454 , A61K31/4709 , A61K31/496 , A61K31/5377 , C07D261/08 , C07D261/10 , C07D413/04 , C07D413/10 , C07D417/04 , C07D495/04
摘要： Isoxazoles of formula (A) or (B) wherein R1 is a group of formula (IB) The isoxazoles are inhibitors of HSP90 activity, and useful for the treatment of, for example, cancers.
摘要翻译：式（A）或（B）的异恶唑其中R1是式（IB）的基团异恶唑是HSP90活性的抑制剂，可用于治疗例如癌症。

85. 发明申请

US20110071175A1 Indoles and Their Therapeutic Use 有权
标题翻译：吲哚及其治疗用途
公开(公告)号：US20110071175A1
公开(公告)日：2011-03-24
申请号：US12746104
申请日：2008-12-12
申请人： George Hynd , John Gary Montana , Harry Finch , Rosa Arienzo , Barbara A. Vitabile-Woo , Mathias Domostoj
发明人： George Hynd , John Gary Montana , Harry Finch , Rosa Arienzo , Barbara A. Vitabile-Woo , Mathias Domostoj
IPC分类号： A61K31/506 , C07D403/06 , A61K31/4178 , C07D417/06 , A61K31/427 , A61K31/405 , C07D417/14 , A61K31/4439 , C07D209/42 , C07D403/12 , A61P11/06 , A61P1/04
CPC分类号： C07D209/12 , C07D209/04 , C07D401/06 , C07D403/06 , C07D403/12 , C07D409/06 , C07D409/14 , C07D417/06 , C07D417/14
摘要： Compound of formula (I) are ligands of the CRTH2 receptor, useful inter alia for treatment of inflammatory conditions. Wherein X is —SO2— or *—SO2NR3— wherein the bond marked with an asterisk is attached to Ar1; R1 is hydrogen, fluoro, chloro, CN or CF3; R2 is hydrogen, fluoro or chloro; R3 is hydrogen, C1C8alkyl or C3-C7cycloalkyl; Ar1 is phenyl or a 5- or 6-membered heteroaryl group selected from furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C3-C7cycloalkyl, —O(C1-C4alkyl) or C1C6alkyl, the latter two groups being optionally substituted by one or more fluoro atoms; and Ar2 is phenyl or 5- or 6-membered heteroaryl group selected from pyrrolyl, furanyl, thienyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridinyl, pyridazinyl, pyrimidinyl and pyrazinyl, wherein the phenyl or heteroaryl groups are optionally substituted by one or more substituents independently selected from fluoro, chloro, CN, C3-C3-C7cycloalkyl, —O(C1-C4alkyl) or C1C6alkyl, the latter two groups being optionally substituted by one or more fluoro atoms.
摘要翻译：式（I）的化合物是CRTH2受体的配体，特别用于治疗炎性病症。其中X是-SO 2 - 或* -SO 2 NR 3 - ，其中用星号附着的键连接到Ar1上; R1是氢，氟，氯，CN或CF3; R2是氢，氟或氯; R3是氢，C1C8烷基或C3-C7环烷基; Ar 1是苯基或选自呋喃基，噻吩基，恶唑基，噻唑基，咪唑基，吡唑基，异恶唑基，异噻唑基，吡啶基，哒嗪基，嘧啶基和吡嗪基的5-或6-元杂芳基，其中苯基或杂芳基任选被一个或更多个独立地选自氟，氯，CN，C 3 -C 7环烷基，-O（C 1 -C 4烷基）或C 1 -C 6烷基的取代基，后两个基团任选被一个或多个氟原子取代; 并且Ar 2是苯基或选自吡咯基，呋喃基，噻吩基，恶唑基，噻唑基，咪唑基，吡唑基，异恶唑基，异噻唑基，吡啶基，哒嗪基，嘧啶基和吡嗪基中的5-或6-元杂芳基，其中苯基或杂芳基任选被取代通过一个或多个独立地选自氟，氯，CN，C 3 -C 3 -C 7环烷基，-O（C 1 -C 4烷基）或C 1 -C 6烷基的取代基，后两个基团任选被一个或多个氟原子取代。

86. 发明授权

US07858640B2 Quinolines and their therapeutic use 有权
标题翻译：喹啉及其治疗用途
公开(公告)号：US07858640B2
公开(公告)日：2010-12-28
申请号：US12066603
申请日：2006-09-29
申请人： Michael Colin Cramp , Rosa Arienzo , George Hynd , Peter Crackett , Yann Griffon , Trevor Keith Harrison , Nicholas Charles Ray , Harry Finch , John Gary Montana
发明人： Michael Colin Cramp , Rosa Arienzo , George Hynd , Peter Crackett , Yann Griffon , Trevor Keith Harrison , Nicholas Charles Ray , Harry Finch , John Gary Montana
IPC分类号： A01N43/42 , A61K31/47 , C07D215/00 , C07D215/38
CPC分类号： C07D215/233 , A61K31/47 , C07D215/12 , C07D215/18 , C07D215/20 , C07D215/227 , C07D215/36 , C07D215/48 , C07D401/04 , C07D401/10 , C07D401/12
摘要： Compounds of formula [1] are CRTH2 antagonists, useful in the treatment of conditions having an inflammatory components; in which: R1-R9 are various substituents; A is —CHR10—, —C(O)—, —S(O)n—, —O—, or —NR10— wherein n is an integer from 0-1 and R10 is selected from various substituents; B is a direct bond or a divalent radical; R11 and R12 are selected from cvarious substituents; X is a carboxylic acid, tetrazole, 3-hydroxyisoxazole, hydroxamic acid, phosphinate, phosphonate, phosphonamide, sulfonic acid group, or a group of formula C═(O)NHSO2R6 or SO2NHC(═O)R6; and Y is aryl, heteroaryl, aryl-fused-heterocycloalkyl, heteroaryl-fused-cycloalkyl, heteroaryl-fused-heterocycloalkyl or aryl-fused-cycloalkyl group.
摘要翻译：式[1]化合物是CRTH2拮抗剂，可用于治疗具有炎性成分的病症; 其中：R 1 -R 9是各种取代基; A是-CHR 10 - ， - C（O） - ， - S（O）n - ， - O-或-NR 10 - ，其中n是0-1的整数，R 10选自各种取代基; B是直接键或二价基团; R 11和R 12选自多个取代基; X是羧酸，四唑，3-羟基异恶唑，异羟肟酸，次膦酸盐，膦酸盐，膦酰胺，磺酸基或式C =（O）NHSO 2 R 6或SO 2 NHC（= O）R 6的基团; 并且Y是芳基，杂芳基，芳基稠合 - 杂环烷基，杂芳基 - 稠合 - 环烷基，杂芳基 - 稠合 - 杂环烷基或芳基稠合 - 环烷基。

87. 发明申请

US20100113540A1 Azole and Thiazole Derivatives and Their Use 审中-公开
公开(公告)号：US20100113540A1
公开(公告)日：2010-05-06
申请号：US12063216
申请日：2006-08-08
申请人： Nicholas Charles Ray , Richard James Bull , Harry Finch , Marco van den Heuvel , Jose Antonio Bravo
发明人： Nicholas Charles Ray , Richard James Bull , Harry Finch , Marco van den Heuvel , Jose Antonio Bravo
IPC分类号： A61K31/421 , C07D263/32 , A61P9/00 , A61P11/06 , A61P13/00
CPC分类号： C07D263/32 , C07D277/28 , C07D413/06 , C07D413/12
摘要： Compounds of formula (I) are useful in the treatment of diseases where enhanced M3 receptor activation is implicated, such as respiratory tract diseases: wherein (i) R1 is C1-C6-alkyl or hydrogen; and R2 is hydrogen or a group —R7, —Z—Y—R7, —Z—NR9R10; —Z—CO—NR9R10, —Z—NR9—[AE11]C(O)O—R7, or —Z—C(O)—R7; and R3 is a lone pair, or C1C6-alkyl; or (ii) R1 and R3 together with the nitrogen to which they are attached form a heterocycloalkyl ring and R2 is a lone pair or a group —R7, —Z—Y—R7, —Z—NR9R10, —Z—CO—NR9R10, —Z—NR9—[AE12]C(O)O—R7; or; —Z—C(O)—R7; or (iii) R1 and R2 together with the nitrogen to which they are attached form a heterocycloalkyl ring, said ring being substituted by a group —Y—R7, —Z—Y—R7, —Z—NR9R10; —Z—CO—NR9R10; —Z—NR9—[AE13]C(O)O—R7; or; —Z—C(O)—R7; and R3 is a lone pair, or C1-C6-alkyl; R4 and R5 are independently selected from the group consisting of aryl, ary-tfused-heterocycloalkyl, heteroaryl, C1-C6-alkyl, cycloalkyl; R6 is —OH, C1-C6-alkyl, C1-C6-alkoxy, hydroxy-C1-C6-alkyl, nitrile, a group CONR82 or a hydrogen atom; A is an oxygen or a sulfur atom; X is an alkylene, alkenylene or alkynylene group; R7 is an C1-C6-alkyl, aryl, aryl-fused-cycloalkyl, aryl-fused-heterocycloalkyl, heteroaryl, aryl(C1-C8-alkyl)-, heteroaryl(C1-C8-alkyl)-, cycloalkyl or heterocycloalkyl group; R8 is C1-C6-alkyl or a hydrogen atom; Z is a C1-C16-alkylene, C2-C16-alkenylene or C2-C16-alkynylene group; Y is a bond or oxygen atom; R9 and R10 are independently a hydrogen atom, C1-C6-alkyl, aryl, aryl-fused-heterocycloalkyl, aryl-fused-cycloalkyl, heteroaryl, aryl(C1-C6-alkyl)-, or heteroaryl(C1-C6-alkyl)- group; or R9 and R10 together with the nitrogen atom to which they are attached form a heterocyclic ring of 48 atoms, optionally containing a further nitrogen or oxygen atom.

88. 发明申请

US20100056565A1 Heterocyclic Derivatives as M3 Muscarinic Receptors 审中-公开
标题翻译：杂环衍生物作为M3毒蕈碱受体
公开(公告)号：US20100056565A1
公开(公告)日：2010-03-04
申请号：US12523609
申请日：2008-02-14
申请人： Barbara Giuseppina Avitabile , Harry Finch , Jamie David Knight , Alan John Nadin , Nicholas Charles Ray
发明人： Barbara Giuseppina Avitabile , Harry Finch , Jamie David Knight , Alan John Nadin , Nicholas Charles Ray
IPC分类号： A61K31/439 , C07D453/02 , A61P11/06 , A61P11/04 , A61P11/08
CPC分类号： C07D471/08
摘要： This invention relates to M3 antagonists of formula (I) wherein R2, R4, R5, R6, W, V, A, D, X, t, u and v are as defined herein; pharmaceutical compositions containing them; methods for their preparation; and their use in the treatment of diseases where enhanced M3 receptor activation is implicated.
摘要翻译：本发明涉及式（I）的M3拮抗剂，其中R 2，R 4，R 5，R 6，W，V，A，D，X，t，u和v如本文所定义; 含有它们的药物组合物; 其准备方法; 以及它们用于治疗涉及M3受体活化增强的疾病。

89. 发明申请

US20100010034A1 CRTH2 ANTAGONISTS 审中-公开
公开(公告)号：US20100010034A1
公开(公告)日：2010-01-14
申请号：US12519979
申请日：2006-12-21
申请人： George Hynd , Nicholas Charles Ray , Harry Finch , David Middlemiss , Michael Colin Cramp , Paul Matthew Blaney , Karen Williams , Yann Griffon , Trevor Keith Harrison , Peter Crackett
发明人： George Hynd , Nicholas Charles Ray , Harry Finch , David Middlemiss , Michael Colin Cramp , Paul Matthew Blaney , Karen Williams , Yann Griffon , Trevor Keith Harrison , Peter Crackett
IPC分类号： A61K31/44 , C07D471/04 , A61P11/00 , A61P1/00
CPC分类号： C07D471/04
摘要： The following compounds are CRTH2 antagonists, useful in treatment of respiratory disease: [3-(2,4-dichlorophenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(2-fluoro-4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(4-methanesulfonyl-2-trifluoromethylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, (R)-2-[6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]propionic acid, [3-(4-ethanesulfonylphenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, (S)-2-[6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]propionic acid, ethanesulfonylaminobenzenesulfonyl)-6-fluoro-2-methyiindolizin-1-yl]acetic acid, [7-chloro-6-fluoro-3-(4-methanesulfonylphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [3-(2-chloro-4-methanesulfonylphenylsulfanyl)-7-cyano-2-methylindolizin-1-yl]acetic acid, [6-cyano-3-(4-methanesulfonylbenzyl)-2-methylindolizin-1-yl]acetic acid, [3-(4-chlorobenzyl)-7-cyano-2-methylindolizin-1-yl]acetic acid, [6-cyano-3-(6-fluoroquinolin-2-yl-methyl)-2-methylindolizin-1-yl]acetic acid, [6-fluoro-3-(4-methoxyphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [7-chloro-6-fluoro-3-(4-methoxyphenylsulfanyl)-2-methylindolizin-1-yl]acetic acid, [3-(4-bromophenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid, and [3-(4-cyclopropylsulfamoylphenylsulfanyl)-6-fluoro-2-methylindolizin-1-yl]acetic acid.
摘要翻译：以下化合物是可用于治疗呼吸系统疾病的CRTH2拮抗剂：[3-（2,4-二氯苯基硫烷基）-6-氟-2-甲基吲哚啉-1-基]乙酸[6-氟-3-（2- （4-甲基磺酰基-2-三氟甲基苯基硫烷基）-2-甲基吲哚哩啶-1-基]乙酸，（R） - （4-氟-4-甲磺酰基苯基硫烷基）-2-甲基吲哚啉-1-基] 2- [6-氟-3-（4-甲磺酰基苯基硫基）-2-甲基吲哚啉-1-基]丙酸，[3-（4-乙磺酰基苯基硫烷基）-6-氟-2-甲基吲哚啉-1-基]乙酸，（S）-2- [6-氟-3-（4-甲磺酰基苯基硫烷基）-2-甲基吲哚啉-1-基]丙酸，乙磺酰氨基苯磺酰基）-6-氟-2-甲基吲哚啉-1-基]乙酸[7 （4-甲磺酰基苯基硫烷基）-2-甲基吲哚哩啶-1-基]乙酸[3-（2-氯-4-甲磺酰基苯基硫烷基）-7-氰基-2-甲基吲哚啉-1-基] ]乙酸[6-氰基-3-（4-甲磺酰基苄基）-2-甲基吲哚啉-1-基]乙酸[3-（4-氯苄基）-7-氰基-2-甲基吲哚吡啶-1-基]乙酸[6-氰基-3-（6-氟喹啉-2-基 - 甲基）-2-甲基吲哚啉-1-基]乙酸[6-氟-3-（4-甲氧基苯基硫烷基）-2-甲基吲哚啉-1-基]乙酸[7-氯-6-氟-3-（4-甲氧基苯基硫烷基）-2-甲基吲哚啉-1-基]乙酸[3-（4-溴苯基硫基） - 6-氟-2-甲基吲哚啉-1-基]乙酸和[3-（4-环丙基氨磺酰基苯基硫烷基）-6-氟-2-甲基吲哚啉-1-基]乙酸。

90. 发明申请

US20090105268A1 Dihydropyrimidone Multimers and Their Use as Human Neutrophil, Elastase Inhibitors 审中-公开
标题翻译：二氢嘧啶酮多聚体及其作为人中性粒细胞，弹性蛋白酶抑制剂的用途
公开(公告)号：US20090105268A1
公开(公告)日：2009-04-23
申请号：US11993699
申请日：2006-06-26
申请人： Harry Finch , Christine Edwards , Nicholas Charles Ray , Mary Frances Fitzgerald
发明人： Harry Finch , Christine Edwards , Nicholas Charles Ray , Mary Frances Fitzgerald
IPC分类号： A61K31/497 , C07D403/12 , A61P11/00
CPC分类号： C07D239/22 , A61K31/513 , A61K47/55 , C07D401/14 , C07D403/14
摘要： A compound of formula M-L-M (I) wherein L is a linker and each M is independently a group of formula (II) is useful in therapy, e.g. of respiratory diseases.
摘要翻译：式M-L-M（I）的化合物，其中L是连接基，每个M独立地是式（II）的基团，可用于治疗，例如，的呼吸系统疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式